Lanzo

Lansoprazole, the active ingredient in Lanzo, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adult patients.

GNH USA supplies Lanzo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for bulk and packaged orders across multiple regulatory markets globally.

Lansoprazole is employed to manage acid‑related disorders by suppressing gastric secretion.

Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation, promotes healing of esophageal mucosa, and reduces acid exposure. Peptic ulcer disease: facilitates ulcer healing by maintaining a higher gastric pH, thereby protecting the ulcer base from acid damage. NSAID‑induced ulcer prevention: reduces the risk of ulcer formation in patients requiring chronic non‑steroidal anti‑inflammatory drug therapy. Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic gastric environment.

Lansoprazole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild headache reported in some patients. - Diarrhea: loose stools or increased frequency. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis may occur. - Acute interstitial nephritis: kidney inflammation presenting with rash and fever. - Osteoporotic fractures: increased risk of hip, wrist or vertebral fractures with long‑term use.

When prescribing lansoprazole, clinicians should consider several safety and handling precautions. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Evaluate for CYP2C19 interactions: genetic variability can affect drug levels. - Monitor for hypomagnesemia: prolonged therapy may lower serum magnesium. - Use caution in elderly: higher risk of bone fractures and infections. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Lansoprazole can alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk. - Atazanavir: decreased absorption leading to loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Digoxin: increased serum levels, observe for toxicity signs. - Methotrexate: higher exposure may cause toxicity, especially at high doses.